Key result
Ouabain exhibits vagomimetic and sympatholytic effects that follow measurable serum concentrations, suggesting it may improve heart failure treatment and warrants clinical re-evaluation.
The authors argue that ouabain, due to its vagomimetic and sympatholytic effects, warrants clinical re-evaluation for heart failure treatment.
Authors
No takes yet. Share an insight, caveat, or question.
No immediate practice change; leaves open ouabain's role in heart failure pending randomized trials.
Hauke Fürstenwerth (2014) conducted a review in Heart failure. Ouabain vs. Digoxin was evaluated. Ouabain exhibits vagomimetic and sympatholytic effects that follow measurable serum concentrations, suggesting it may improve heart failure treatment and warrants clinical re-evaluation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: